Roth Capital set a $24.00 price target on Recro Pharma Inc. (NASDAQ:REPH) in a report released on Monday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on REPH. Zacks Investment Research upgraded shares of Recro Pharma from a hold rating to a buy rating and set a $8.75 target price for the company in a research report on Wednesday, October 19th. Brean Capital started coverage on shares of Recro Pharma in a research report on Monday, October 3rd. They issued a buy rating and a $21.00 target price for the company. Janney Montgomery Scott started coverage on shares of Recro Pharma in a research report on Monday, August 29th. They issued a buy rating and a $21.00 target price for the company. HC Wainwright reiterated a buy rating on shares of Recro Pharma in a research report on Monday, November 14th. Finally, Aegis started coverage on shares of Recro Pharma in a research report on Monday, November 14th. They issued a buy rating and a $21.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $19.15.

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) traded down 5.91% during trading on Monday, reaching $8.75. 473,856 shares of the company’s stock were exchanged. The company’s market capitalization is $106.43 million. Recro Pharma has a 1-year low of $5.59 and a 1-year high of $12.50. The company’s 50-day moving average is $7.71 and its 200-day moving average is $8.33.

TRADEMARK VIOLATION NOTICE: This piece of content was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/29/recro-pharma-inc-reph-given-a-24-00-price-target-at-roth-capital.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in REPH. BlackRock Fund Advisors increased its position in shares of Recro Pharma by 37.5% in the second quarter. BlackRock Fund Advisors now owns 15,268 shares of the specialty pharmaceutical company’s stock valued at $121,000 after buying an additional 4,163 shares during the period. Northern Trust Corp purchased a new position in shares of Recro Pharma during the third quarter valued at approximately $128,000. Acadian Asset Management LLC purchased a new position in shares of Recro Pharma during the third quarter valued at approximately $140,000. Wells Fargo & Company MN increased its position in shares of Recro Pharma by 56.0% in the third quarter. Wells Fargo & Company MN now owns 31,200 shares of the specialty pharmaceutical company’s stock valued at $276,000 after buying an additional 11,200 shares during the period. Finally, BlackRock Institutional Trust Company N.A. increased its position in shares of Recro Pharma by 30.5% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 49,947 shares of the specialty pharmaceutical company’s stock valued at $397,000 after buying an additional 11,682 shares during the period. Hedge funds and other institutional investors own 52.28% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

5 Day Chart for NASDAQ:REPH

Receive News & Stock Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related stocks with our FREE daily email newsletter.